My prediction is actually > $100 a share eventually. We know MHRA approval is coming, there is NOTHING that is showing this will not be approved, I mean a UK Bill is going through parliament that was pretty much designed as per Linda Powers testimony.
HERE WE GO:
There are ~15,000 GBM cases in the US, 3,200 in the UK, and 22,000 in Europe every year. Take all 3,200 of the UK alone even at £100K per vaccine as it is on the high medicine cost list. Also it is good to note that I am using £100K and it will probably be higher as certain rare disease treatments can be even more expensive, sometimes exceeding £250,000 annually. Some cancer treatments or biologics may cost between £10,000 to over £100,000 per year.
Using £100K, that gives a revenue of £320 Million alone. Include 1/4 of Europe and 10% of the US that will fly to the UK to be treated; that is another £690 Million for a total of nearly £1B just from Europe and THAT IS CONSERVATIVE CASE. So we know it will be somewhere between £690 Million and £2.5 Billion. And that is GBM alone. Imagine what the revenue would be for unoperable cancers in combo with checkpoint inhibitors.... With GBM sales in the UK alone, this should be a $30 a share stock. Now they would need to scale up their manufacturing in Sawston, but it is very evident that they will be able to receive significant revenue right off the bat.
AI
Market Data 
Markets 
